In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.
“We support the new administration s plan to vaccinate as many people as quickly as possible because there is an urgent need to help protect people from this virus, here in the U.S. and across the globe,” said
Albert Bourla, Chairman and Chief Executive Officer, Pfizer. We are pleased to work with the administration to provide these additional vaccines, so that more Americans receive their first and second doses as soon as possible.
U.S. government exercises option to bring total supply to 300 million doses, enabling vaccinations for 150 million people NEW YORK and MAINZ, GERMANY, February 12, 2021 - Pfizer Inc.(Nasdaq: BNTX)
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
New York, NY and Mainz, Germany, February 1, 2021 (GLOBE NEWSWIRE)
BioNTech SE (Nasdaq: BNTX) today announced that preclinical data in non-human primate and mouse models from Pfizer and BioNTech’s mRNA-based vaccine candidates, BNT162b1 and BNT162b2, for the prevention of COVID-19 were published in the journal
Nature. Some of these data were initially made available to the public on September 9, 2020 via the online preprint server,
bioRxiv. For additional details, please read the previously issued
The preclinical data found immunization of rhesus macaques with either the BNT162b1 or BNT162b2 vaccine candidate elicited SARS-CoV-2 neutralizing geometric mean titers 8.2 to 18.2 times that of a SARS-CoV-2 convalescent human serum panel. Additionally, the vaccine candidates protected macaques from SARS-CoV-2 challenge, with BNT162b2 protecting the lower respiratory tract from